|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
FY2020
12 months to Dec 31, 2020
|
|
|---|---|---|---|---|
| Revenue | ||||
| Revenue from contract with customer | ||||
| Operating expense: | ||||
| Cost of revenue | ||||
| Research and development | ||||
| Selling, general, and administrative | ||||
| Restructuring and related charges | ||||
| Total operating expenses | ||||
| Loss from operations | ||||
| Other income (expense): | ||||
| Change in fair value of private placement warrant liability | ||||
| Change in fair value of earnout liability | ||||
| Foreign currency exchange loss and other expense | ||||
| Interest expense, net | ||||
| Gain (loss) on equity securities | ||||
| Foreign currency exchange loss and other expense, net | ||||
| Investment income and interest income, net | ||||
| Total other income (expense) | ||||
| Loss before income taxes | ||||
| Income tax expense (benefit) | ||||
| Net loss | ||||
| Foreign currency translation adjustment | ||||
| Available-for-sale short-term investments: | ||||
| Comprehensive loss | ||||
| Less: Comprehensive income (loss) attributable to noncontrolling interest | ||||
| Comprehensive loss attributable to Hyzon | ||||
| Net loss per share attributable to Hyzon: | ||||
| Basic (in dollars per share) | ||||
| Diluted (in dollars per share) | ||||
| Weighted average common shares outstanding: | ||||
| Basic (in shares) | ||||
| Diluted (in shares) | ||||
| Less: Net gain (loss) attributable to noncontrolling interest | ||||
| Net loss attributable to Hyzon | ||||
Loading...